Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 190.43

-0.7%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Abuckatatime who wrote (7656)	9/25/1997 4:01:00 PM
From: Henry Niman	of 32384

Greg, There are only three compounds in the clinic right now, Targretin, Panretin, and ALRT1550. I assume that ALRT326 and ALRT4204 would have applications for diabetes because RXRalpha is the key receptor on the rexinoid side and I haven't seen anything indicating that "RXR selective" compounds show anything more than distiguishing between the 3 RXRs and the 3 RARs. Energy metabolism and cardiovascular applications seem to involve PPAR alpha and I'm not sure that the precise RXR partner has been identified. Thus, Targretin and ALRT268 have applications in all three areas and I assume ALRT326 and ALRT4204 do also. I have to dig out ALRT's annual report to start sorting out the players, but my recolection does not include any RXR selective compound that shows subtype specificities among the RXRs. The site for new drugs (but I don't think that they even have ALRT1550) in 1997 is: ascp.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next